Influence of low-grade inflammation on plasma B-type natriuretic peptide levels

Internal Medicine

Volumn 49, Issue 24, 2010, Pages 2659-2668

  Inoue, Terumasa ^a   Kawai, Makoto ^a   Nakane, Tokiko ^a   Nojiri, Ayumi ^a   Minai, Kosuke ^a   Komukai, Kimiaki ^a   Ogawa, Takayuki ^a   Hongo, Kenichi ^a   Matsushima, Masato ^a   Yoshimura, Michihiro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Heart failure; Left ventricular end systolic dimension; Serum c reactive protein and prognosis

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CORONARY CARE UNIT; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; SEVERITY OF ILLNESS INDEX;

EID: 78650313825     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.4211     Document Type: Article

References (51)

1. Kangawa K, Tawaragi Y, Oikawa S, et al. Identification of rat gamma atrial natriuretic polypeptide and characterization of the cDNA encoding its precursor. Nature 312: 152-155, 1984.
2. De Bold AJ. Arterial natriuretic factor: a hormone produced by the heart. Science 230: 767-770, 1985.
3. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 332: 78-81, 1988.
4. Ito T, Yoshimura M, Nakamura S, et al. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 107: 807-810, 2003.
5. Yasue H, Obata K, Okumura K, et al. Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy. J Clin Invest 83: 46-51, 1989.
6. Saito Y, Nakao K, Arai H, et al. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest 83: 298-305, 1998.
7. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic pep-tide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87: 1402-1412, 1991.
8. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195-203, 1994.
9. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87: 464-469, 1993.
10. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88: 82-91, 1993.
11. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in car-diocyte hypertrophy: Evidence for brain natriuretic peptide as an 'emergency' cardiac hormone against ventricular overload. J Clin Invest 96: 1280-1287, 1995.
12. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96: 509-516, 1997.
13. Boerrigter G, Costello-Boerrigter LC, Burnett JC Jr. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin 5: 501-514, 2009.
14. Shapiro BP, Chen HH, Burnett JC Jr, Redfield MM. Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc 78: 481-486, 2003.
15. Mizuno Y, Yoshimura M, Harada E, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardio-myopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 86: 1036-1040, 2000.
16. Harada M, Itoh H, Nakagawa O, et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: Evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 96: 3737-3744, 1997.
17. Kuwahara K, Saito Y, Harada M, et al. Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocyte in vitro. Circulation 100: 1116-1124, 1999.
18. Harada M, Itoh H, Nakagawa O, et al. Effect of interleukin-lB on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. J Mol Cell Cardiol 31: 1997-2006, 1999.
19. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864-874, 1992.
20. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252: 283-294, 2002.
21. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New Eng J Med 350: 1387-1397, 2004.
22. Labarrere CA, Lee JB, Nelson DR, Al-Hassani M, Miller SJ, Pitts DE. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 360: 1462-1467, 2002.
23. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. New Engl J Med 359: 1897-1908, 2008.
24. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. New Engl J Med 351: 2599-2610, 2004.
25. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New Engl J Med 347: 1557-1565, 2002.
26. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, ho-mocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285: 2481-2485, 2001.
27. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
28. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. New Engl J Med 352: 20-28, 2005.
29. Suzuki S, Yoshimura M, Nakayama M, et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocar-dial infarction: a long-term follow-up analysis. Circulation 110: 1387-1391, 2004.
30. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350: 655-663, 2004.
31. Anand IS, Fisher LD, Chiang YT, et al. For the Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107: 1278-1283, 2003.
32. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic pep-tide predicts sudden death in patients with chronic heart failure. Circulation 105: 2392-2397, 2002.
33. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriu-retic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93: 1963-1969, 1996.
34. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107: 2786-2792, 2003.
35. Scott PA, Barry J, Roberts PR, Morgan JM. Brain natriuretic pep-tide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J Heart Fail 11: 958-966, 2009.
36. Di Angelantonio E, Chowdhury R, Sarwar N, et al. B-type natriu-retic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 120: 2177-2187, 2009.
37. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55: 613-618, 1977.
38. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5: 303-311, 1989.
39. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130: 461-470, 1999.
40. Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.
41. Bankers-Fulbright JL, Kalli KR, NcKean DJ. Interleukin-1 signal transduction. Life Sciences 59: 61-83, 1996.
42. Barnes PJ, Karin M. Nuclear factor kappa B: Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997.
43. He Q, Lapointe MC. Interleukin-1 beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 33: 283-289, 1999.
44. Kuwahara K, Saito Y, Harada M, et al. Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation 100: 1116-1124, 1999.
45. Hare JM. Oxidative stress and apoptosis in heart failure progression. Circulation Research 89: 198-200, 2001.
46. Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for rat brain natri-uretic peptide. Biochem Biophys Res Commun 159: 1420-1426,1989.
47. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 389: 39-48, 1982.
48. Lei K-J, Liu T, Zon G, Soravia E, Liu T-Y, Goldman ND. Genomic DNA sequence for human C-reactive protein. J Biol Chem 260: 13377-13383, 1985.
49. Usuku H, Nakayama M, Sumida H, et al. Pump failure death and sudden cardiac death in patients with cardiac dysfunction: A search for prognostic predictive factors-A long-term follow-up study. J Cardiol 55: 55-64, 2010.
50. Saito Y, Nakao K, Nishimura K, et al. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation 76: 115-124, 1987.
51. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84: 1581-1588, 1991.